Sameer Zar - The Royal Marsden

More documents

Recommendations

Info

40 The Royal Marsden Barrett’s Oesophagus with Low Grade Dysplasia – Darker Hyperchromatic – Cytological atypia – 2.7 – 3.4% per yr progress to HGD/Cancer over a mean follow up of 5-8 yrs
41 The Royal Marsden Management of Barrett’s Oesophagus with Low Grade Dysplasia – Treatment of reflux disease – PPI (H2 antagonists are inadequate) – Anti-reflux surgery – Screening endoscopy for dysplasia every 6-12 months – ?Chemoprevention – ?Ablation/Surgery
Page 1 and 2: The Royal Marsden Barrett’s Oesop
Page 3 and 4: 3 The Royal Marsden Diagnosis of Ba
Page 5 and 6: 5 The Royal Marsden Clinical Featur
Page 7 and 8: 7 The Royal Marsden Risk Factors As
Page 9 and 10: 9 The Royal Marsden Change Presenta
Page 11 and 12: The Royal Marsden Change Presentati
Page 17 and 18: 17 The Royal Marsden Surveillance o
Page 19 and 20: 19 The Royal Marsden Risk Factors A
Page 21 and 22: 21 The Royal Marsden Screening For
Page 23 and 24: 23 The Royal Marsden Change Present
Page 25 and 26: 25 The Royal Marsden Screening and
Page 27 and 28: How to Improve Screening for Barret
Page 31 and 32: 31 The Royal Marsden Managing Cance
Page 35 and 36: 35 The Royal Marsden Cancer Risk in
Page 37 and 38: 37 The Royal Marsden Management of
Page 39: 39 The Royal Marsden Twice Daily do
Page 43 and 44: 43 The Royal Marsden Management opt
Page 49 and 50: 49 The Royal Marsden Endoscopic Muc
Page 53 and 54: 53 The Royal Marsden ESD for Barret
Page 55 and 56: 55 The Royal Marsden Endotherapy in
Page 57 and 58: The Royal Marsden Primary Preventio
Page 59: The Royal Marsden Conclusion - Scre

Sameer Zar - The Royal Marsden

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?